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JOURNAL OF HEPATOLOGYIs there any association between HCV multiplication and
iron induced liver injury in chronic hepatitis C?To the Editor:
We were very interested in the excellent paper by Fillebeen
et al. published in a recent issue of the Journal of Hepatology
[1]. The paper presents unexpected results on the role of iron
in hepatitis C virus (HCV) replication. The authors conﬁrm
the results of a previous publication and show, in in vitro
experiments, the iron-mediated inhibition of HCV replication.
These results are surprising and are not consistent with
those of earlier studies in which iron was implicated in the
upregulation of HCV translation [2,3] or the enhancement of
HCV replication [4]. These results are also intriguing in the
context of clinical observations of patients with chronic hepati-
tis C (CHC). It is rather difﬁcult to determine a simple correla-
tion between the iron-induced inhibition of HCV replication
and the less favourable prognosis of CHC patients with iron
overload [5].
The attempt to apply the results of the experimental models
to clinical situations, according to some selected reports, is
quite risky. Fillebeen et al. cited three previous reports showing
the association of HFE gene mutations, an etiologic agent of
HFE hemochromatosis, with efﬁcacy of antiviral treatment. Per-
haps, they selected these papers because of the possible asso-
ciations between iron concentration, intensity of HCV
multiplication, and viral load, which is a known strong predic-
tor of SVR.
Distante et al. found that C282Y mutations (2 C282Y homo-
zygotes and 31 C282Y heterozygotes) were independent predic-
tors of SVR but this effect was probably caused by a lack of HFE
phenotypic expression and by factors that were associated with
the virus. In their study, carriers of C282Y mutations did not
show any signiﬁcant increase in serum concentrations of ferri-
tin nor increased transferrin saturation compared to patients
with wild type HFE. Moreover, the authors stated that serum
ferritin concentration was predictive of non-response to inter-
feron and ribavirin therapy [6]. Based on our own observations,
two out of 152 CHC patients with iron overload were homozy-
gous for the C282Y mutation and died at the age of 40, with
rapidly progressive liver failure due to liver cirrhosis and hepa-
tocellular carcinoma, after unsuccessful antiviral therapies. Leb-
ray et al. did not conﬁrm that the H63D mutation was a
signiﬁcant predictor of SVR (p = 0.089) [7]. In a large study by
Bonkovsky et al., iron and HFE gene mutations were analysed
in relation to PEG-IFN therapy in advanced CHC patients. A pos-
sible positive inﬂuence of HFE mutations on the effectiveness of
antiviral therapy was found, especially with the H63D muta-
tion, but only in patients without conﬁrmed hereditary hemo-
chromatosis or iron overload based on a liver biopsy.
Moreover, the presence of iron deposits in hepatocytes did
not affect the rate of SVR [8].
In contrast, in our study, we found that treatment failure
was positively correlated with elevated iron serum concentra-
tion and the presence of HFE gene mutations, in 61 out of
152 CHC patients treated with PEG-IFN plus ribavirin. However,
HFE gene mutations did not appear to be the main factor
responsible for iron overload in CHC [9]. In conclusion, addi-
tional experiments on cellular models and clinical studies are
required to elucidate the impact of iron on HCV replication
in terms of the pathogenesis of acute and chronic HCV infec-
tion and to explain the differences between clinical and exper-
imental observations.
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Reply to: Is there any association between HCV multiplication
and iron induced liver injury in chronic hepatitis C?
This is a reply to the letter to the Editor by Sikorska et al.:
We appreciate the interest of Sikorska et al. in our recent study
[1] and would like to comment on the issues raised in their let-
ter. We fully agree that, in light of clinical literature and earlier
biochemical evidence, the iron-mediated inhibition of HCV rep-
lication is surprising. This matter has been extensively discussed
in a previous related publication [2], which established that iron
attenuates the expression of subgenomic HCV replicons in cul-
ture and blocks the enzymatic activity of recombinant HCV
polymerase NS5B in vitro. Our recent study validated the antivi-
ral activity of iron in a more physiologically relevant setting of
infectious HCV in permissive Huh7.5.1 cells. Certainly, HCV rep-
licon models do not recapitulate the entire range of molecular
responses triggered in the host during acute infection with
HCV and progression to CHC; nevertheless, they provide a valu-
able framework to elucidate important aspects of HCV biology
in a reductionist approach. The employment of such models
uncovered that iron inhibits HCV replication. We speculated
that this surprising ﬁnding may account for some unexpected
clinical observations, where HCV-infected patients with muta-
tions in the HFE gene responded better to antiviral therapy
[3–5].
Sikorska et al. challenge this idea by arguing that it is merely
supported by selected reports. We believe that published clinical
literature qualiﬁes to accommodate hypotheses arising from bio-
chemical data. Moreover, we wish to emphasise that an increased
frequency of HFE gene mutations in HCV patients who are
responders to antiviral therapy has been documented in major
clinical studies (reviewed in [6]). Thus, in a cohort of 256 CHC
patients, the presence of HFE C282Y mutation positively corre-
lated with sustained response in multivariate analysis
(p = 0.012) [3]. Likewise, CHC patients with HFE H63D mutation
showed a signiﬁcant improvement in both their primary
response and sustained response to interferon, although statisti-
cal signiﬁcance for the latter did not reach the level of 0.05 [5].
These data suggested that HFE may constitute part of a battery
of host genes that affect responses to antiviral therapy. Similarly,
in the largest study thus far, on the effects of HFE-related iron
overload in anti-HCV therapy (HALT-C trial) that included 1051
patients, Bonkovsky et al. found that subjects harboring HFE
mutations, particularly H63D, had signiﬁcantly higher likelihood
of both end-of-treatment virological response (p = 0.0078) and
sustained virological response (p = 0.009) to re-treatment with
pegylated interferon alpha-2a plus ribavirin [4]. Again, both the
HFE mutation and/or associated genetic variants were considered
as possible causes of the improved response to therapy.
The iron-dependent inhibition of HCV replication documented
in our studies is consistent with the above clinical ﬁndings and it
is tempting to speculate that even minimal HFE-related hepatic
iron overload may contribute to viral clearance in HCV-infected
patients subjected to antiviral treatment. There is no doubt that
this hypothesis requires further validation in animal models of
HCV infection. It should also be noted that the adverse effects
of iron overload in the liver and in the immune system preclude
any exploitation of the iron-dependent inhibition of HCV replica-
tion for therapeutic purposes.
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